Prevention of RSV disease in babies starts at HUS hospitals
RSV (respiratory syncytial virus) is the most common cause of respiratory infections leading to infant hospitalization. HUS offers an antibody called nirsevimab developed against the RS virus to infants and children under 12 months old who are at risk of severe RSV infection.
HUS will offer nirsevimab to newborns in all its maternity hospitals from September 4, 2025. Nirsevimab is offered to children under the age of 12 months who belong to high-risk groups for a severe RSV disease when they have an appointment in specialized healthcare at HUS New Children's Hospital, Jorvi Hospital, or Hyvinkää Hospital.
The aim of nirsevimab is to prevent the majority of severe illnesses and infant hospitalizations caused by RSV. Immunization with nirsevimab is voluntary and free of charge for families.
Nirsevimab is effective in preventing RSV infections
Nirsevimab can be administered even to newborns. The antibody provides effective protection against RSV for the entire winter epidemic. The product is very safe.
Nirsevimab was used two years ago in several countries, where it prevented 80–90% of hospitalizations caused by RSV. HUS offered nirsevimab to all newborns and children in at-risk groups for the first time in winter 2024–2025. Approximately 90% of infants and babies under the age of three months received the product then. In HUS hospitals, it was estimated that nirsevimab decreased the number of hospitalizations caused by RSV by 70%.
“Hospitalization of a baby is always a difficult experience for the family. In babies, RSV causes severe respiratory symptoms that often need to be treated in a hospital. We are extremely happy that we can offer nirsevimab to our patients,” says Tea Nieminen, specialist in pediatric infectious diseases at HUS New Children's Hospital.
Keywords
Contacts
Administrative Chief Physician Päivi Miettinen, tel. 050 427 2431, paivi.miettinen@hus.fi
Specialist in Pediatric Infectious Diseases Tea Nieminen, tel. 050 428 7406, tea.nieminen@hus.fi
HUS Children and Adolescents
Links
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Helsingfors kardiologiska verksamhet övergår till HUS i början av september28.8.2025 10:19:49 EEST | Pressmeddelande
Kardiologin, det vill säga undersökningarna och behandlingarna av hjärtsjukdomar vid Helsingfors stads internmedicinska poliklinik övergår till HUS den 1 september 2025. I och med förändringen övergår Helsingfors kardiologiska tjänster, personal och utrustning till HUS.
Helsingin kardiologinen toiminta siirtyy HUSiin syyskuun alussa28.8.2025 10:19:49 EEST | Tiedote
Helsingin kaupungin sisätautien poliklinikan kardiologian eli sydänsairauksien tutkimus ja hoito siirtyy 1.9.2025 osaksi HUSia. Muutoksen myötä HUSiin siirtyvät Helsingin kardiologiset palvelut, henkilöstö ja laitteet.
Helsinki’s cardiology services will transfer to HUS in early September28.8.2025 10:19:49 EEST | Press release
Cardiology services, meaning the examination and treatment of heart diseases, currently provided by the Internal Medicine Outpatient Clinic of the City of Helsinki will become part of HUS as of September 1, 2025. As part of this transition, Helsinki’s cardiology services, personnel, and equipment will be transferred to HUS.
HUS-sammanslutningens resultat för januari–juni visade som planerat ett överskott18.8.2025 14:37:47 EEST | Pressmeddelande
HUS-sammanslutningens styrelse som tillsattes i juni inledde sin mandatperiod med sitt första möte. Sammanslutningens styrelse behandlade bland annat HUS-sammanslutningens verksamhet och ekonomi i januari–juni och fick en översikt över läget för verkställande direktörens resultatmål.
HUS-yhtymän tammi−kesäkuun tulos suunnitellusti ylijäämäinen18.8.2025 14:26:32 EEST | Tiedote
HUSin kesäkuussa valittu yhtymähallitus aloitti toimikautensa ensimmäisellä kokouksellaan. Yhtymähallitus käsitteli muun muassa HUS-yhtymän tammi−kesäkuun toimintaa ja taloutta ja sai katsauksen toimitusjohtajan tulostavoitteiden tilanteesta.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom